| Up
2006D-0296:
International Conference on Harmonisation; Draft Guidance on Q4B
Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria;
Annex on Residue on Ignition/Sulphated Ash General Chapter
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| Document #
|
| Received Date
|
| Filed
Date
|
| Submitter Code
|
| Submitter
|
| FR
Date
|
| FR
Page
|
| Comment Date
|
| Files
|
| Remarks
|
|
|
|
|
| GDL1
|
| 08/07/2006
|
| 08/07/2006
|
| Federal Government
|
| Guidance
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
|
| Signature:
|
| Guidance
|
|
|
|
|
|
|
|
| NAD1
|
|
|
| 08/07/2006
|
| FDA
|
| FDA
|
| 08/08/2006
|
| 45058-45059
|
| 10/10/2006
|
| htm
pdf
|
|
|
|
|
| Signature:
|
| JeffreyShuren
|
|
|
|
|
| C1
|
| 10/10/2006
|
| 10/06/2006
|
| Drug Industry
|
| Wyeth Pharmaceuticals, Inc.
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
| Signature:
|
| Roy J. Baranello, Jr.
|
|
|
|
|
| C2
|
| 10/11/2006
|
| 10/10/2006
|
| Drug Industry
|
| Sanofi-Synthelabo Inc and Aventis Pharmaceuticals
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
| Signature:
|
| Richard Gural
|
|
|
|
|
| EMC1
|
| 10/11/2006
|
| 10/10/2006
|
| Private Industry
|
| Merck Research Laboratories/U. S. Regulatory Policy
|
|
|
|
|
|
|
| pdf
|
| CF 2006D-0297/EMC1
|
|
|
| Signature:
|
| Carolyn Peterson
|
|
|
|
|
| C3
|
| 11/01/2006
|
| 10/30/2006
|
| Drug Industry
|
| Schering-Plough
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
| Signature:
|
| Gretchen Trout
|
|
|
|
|
|
Top | Up
Page last updated
November 21, 2006
kk
Dockets Home Page | Dockets
Contacts and Location | Operating
Status | Item
Code Definitions | Federal
Register
FDA Home Page | Search
FDA Site | FDA A-Z Index
| Contact FDA
FDA/Dockets Management |
